Ginkgo Biloba vs Desmopressin in Treatment of Children With Monosymptomatic Nocturnal Enuresis

Ginkgo Biloba Versus Desmopressin in Treatment of Children With Monosymptomatic Nocturnal Enuresis: A Randomized Prospective Study

the efficacy of Ginkgo Biloba versus desmopressin in treatment of children with monosymptomatic nocturnal enuresis

Study Overview

• Status: Completed
• Conditions: Monosymptomatic Nocturnal Enuresis; Desmopressin; Nocturnal Enuresis in Children
• Intervention / Treatment: Drug: Ginkgo Biloba oral tablet; Drug: Desmopressin Acetate 0.2 mg Tablets; Drug: Desmopressin like Placebo; Drug: Ginkgo Biloba like Placebo

Detailed Description

Bedwetting among children is a common disorder, affecting 30% at age 4, 10% at age 6, 3% at age 12, and 1% at age. Untreated, the spontaneous cure rate is about 15% a year. Treatment is dominated by two approaches, enuresis alarm and drugs.

Treatment with drugs has largely been focused on tricyclic antidepressants especially imipramine or, more recently, antidiuretic agents such as desmopressin. For imipramine the proportion of total remission is 10-50% during treatment and a long term cure in 5-40%. However, numerous reports of side effects, some lethal, have led to a decline in its use.

One of theory of nocturnal enuresis is deep sleep in children, this the main cornerstone in using Alarm as line of management.

On the other hand drugs used in re-habitation of sleep rhythm seems to be with great benefits in management as GINKGO BILOBA.

Ginkgo biloba leave extract is among the most widely sold herbal dietary supplements in the United States. Its purported biological effects include: scavenging free radical; lowering oxidative stress; reducing neural damages, reducing platelets aggregation; anti-inflammation; anti-tumor activities; anti-aging, and improve night sleep rhythm.

the aim of this study is to evaluate the effect of Ginkgo Biloba versus desmopressin in treatment of children with monosymptomatic nocturnal enuresis.

• Study Type: Interventional
• Enrollment (Actual): 398
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Egypt
  • Menoufia
    • Shebin El-Kom, Menoufia, Egypt, 32511
      • Menoufia Faculty of Medicine

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• all children with monosymptomatic nocturnal enuresis.

Exclusion Criteria:

• children with day and night wetting.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Ginkgo Biloba group; Patients in this group receive Ginkgo Biloba oral tablet.	Drug: Ginkgo Biloba oral tablet; patients receive Ginkgo Biloba oral tablet 120 mg once daily; Drug: Desmopressin like Placebo; patients receive Desmopressin like Placebo oral tablet once daily
Active Comparator: Desmopressin group; Patients in this group receive Desmopressin oral tablets.	Drug: Desmopressin Acetate 0.2 mg Tablets; patient receives desmopressin 0.2 mg oral tablet once daily; Drug: Ginkgo Biloba like Placebo; patients receive Ginkgo Biloba like Placebo oral tablet once daily
Experimental: Combination group; Patients in this group receive both Ginkgo Biloba and desmopressin oral tablets.	Drug: Ginkgo Biloba oral tablet; patients receive Ginkgo Biloba oral tablet 120 mg once daily; Drug: Desmopressin Acetate 0.2 mg Tablets; patient receives desmopressin 0.2 mg oral tablet once daily
Placebo Comparator: Placebo group; Patients in this group receive Placebo oral tablet.	Drug: Desmopressin like Placebo; patients receive Desmopressin like Placebo oral tablet once daily; Drug: Ginkgo Biloba like Placebo; patients receive Ginkgo Biloba like Placebo oral tablet once daily

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Night wetting frequency	Night wetting frequency is measured by the number of wet nights per week.	1, 3 months

Collaborators and Investigators

• Sponsor: Menoufia University

Study record dates

Study Major Dates

• Study Start (Actual): November 1, 2024
• Primary Completion (Actual): December 1, 2025
• Study Completion (Actual): January 1, 2026

Study Registration Dates

• First Submitted: January 7, 2025
• First Submitted That Met QC Criteria: January 7, 2025
• First Posted (Actual): January 13, 2025

Study Record Updates

• Last Update Posted (Actual): January 13, 2026
• Last Update Submitted That Met QC Criteria: January 9, 2026
• Last Verified: September 1, 2025

More Information

Terms related to this study

• Keywords: desmopressin; Ginkgo Biloba; nocturnal enuresis; monosymptomatic nocturnal enuresis
• Additional Relevant MeSH Terms: Urogenital Diseases; Mental Disorders; Male Urogenital Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urination Disorders; Behavioral Symptoms; Elimination Disorders; Behavior; Enuresis; Nocturnal Enuresis; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Peptide Hormones; Neuropeptides; Peptides; Amino Acids, Peptides, and Proteins; Oligopeptides; Nerve Tissue Proteins; Proteins; Plant Extracts; Plant Preparations; Biological Products; Complex Mixtures; Pituitary Hormones, Posterior; Pituitary Hormones; Arginine Vasopressin; Vasopressins; Deamino Arginine Vasopressin; Ginkgo Extract
• Other Study ID Numbers: Ginkgo Biloba vs Desmopressin

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No